Insider · CIK 0001958023
Michelle Yanez
Files at INTI (Inhibitor Therapeutics, Inc.), MIRA (MIRA PHARMACEUTICALS, INC.). First filing -, latest -.
Michelle Yanez files SEC Form 4 as CFO and director at INTI (Inhibitor Therapeutics, Inc.), and also at MIRA (MIRA PHARMACEUTICALS, INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Michelle Yanez has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 1, 2025 | INTI Inhibitor Therapeutics, Inc. | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 896,271 | Apr 7, 2025 |
| Dec 9, 2024 | MIRA MIRA PHARMACEUTICALS, INC. | AGrant or award Stock Options (right to buy)derivative | +150,000 | $0.00 | $0 | 150,000 | Dec 10, 2024 |
Questions about Michelle Yanez
Answered from the filings on this page, as of the latest one.
Is Michelle Yanez buying or selling?
Michelle Yanez has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Michelle Yanez's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Michelle Yanez has 0.
Where does Michelle Yanez file Form 4?
Michelle Yanez has filed Form 4 at INTI (Inhibitor Therapeutics, Inc.); MIRA (MIRA PHARMACEUTICALS, INC.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.